Evidence map›Paper›PMID 38639546›Full record

GuidelineAnnals of internal medicine2024

Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians.

Amir Qaseem, Adam J Obley, Tatyana Shamliyan, Lauri A Hicks, Curtis S Harrod, Carolyn J Crandall, Clinical Guidelines Committee of the American College of Physicians, Ethan M Balk, Thomas G Cooney, J Thomas Cross and 9 more

Open access · greenAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Annals of internal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 3 pooled it
28.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 3 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Observational
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

Amir QaseemAmerican College of Physicians, Philadelphia, Pennsylvania (A.Q., T.S., C.H.S.).ORCID 0000-0001-6866-7985
Adam J ObleyPortland Veterans Affairs Medical Center and Oregon Health & Science University, Portland, Oregon (A.J.O.).
Tatyana ShamliyanAmerican College of Physicians, Philadelphia, Pennsylvania (A.Q., T.S., C.H.S.).ORCID 0000-0003-3584-2008
Lauri A HicksCenters for Disease Control and Prevention, Atlanta, Georgia (L.A.H.).ORCID 0000-0002-2383-9357
Curtis S HarrodAmerican College of Physicians, Philadelphia, Pennsylvania (A.Q., T.S., C.H.S.).ORCID 0000-0001-8580-7150
Carolyn J CrandallDavid Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California (C.J.C.).
Clinical Guidelines Committee of the American College of Physicians
Ethan M Balk
Thomas G Cooney
J Thomas Cross
Nick Fitterman
Jennifer S Lin
Michael Maroto
Matthew C Miller
Paul Shekelle
Jeffrey A Tice
Janice E Tufte
Itziar Etxeandia-Ikobaltzeta
Jennifer Yost
American College of Physicians · USCenters for Disease Control and Prevention · USOregon Health & Science University · USUniversity of California, Los Angeles · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

descriptionThe American College of Physicians (ACP) developed this clinical guideline to update recommendations on newer pharmacologic treatments of type 2 diabetes. This clinical guideline is based on the best available evidence for effectiveness, comparative benefits and harms, consideration of patients' values and preferences, and costs.

methodsThis clinical guideline is based on a systematic review of the effectiveness and harms of newer pharmacologic treatments of type 2 diabetes, including glucagon-like peptide-1 (GLP-1) agonists, a GLP-1 agonist and glucose-dependent insulinotropic polypeptide agonist, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, and long-acting insulins, used either as monotherapy or in combination with other medications. The Clinical Guidelines Committee prioritized the following outcomes, which were evaluated using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach: all-cause mortality, major adverse cardiovascular events, myocardial infarction, stroke, hospitalization for congestive heart failure, progression of chronic kidney disease, serious adverse events, and severe hypoglycemia. Weight loss, as measured by percentage of participants who achieved at least 10% total body weight loss, was a prioritized outcome, but data were insufficient for network meta-analysis and were not rated with GRADE. AUDIENCE AND PATIENT POPULATION: The audience for this clinical guideline is physicians and other clinicians. The population is nonpregnant adults with type 2 diabetes. RECOMMENDATION 1: RECOMMENDATION 2:

Indexed as

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsAdultDrug Therapy, CombinationGlucagon-Like Peptide 1HumansInsulinDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide 1Hypoglycemic AgentsInsulinSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID38639546
PMCPMC11614146
OpenAlexW4394942565

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.